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Alemtuzumab, ﬂudarabine, and melphalan reduced-intensity conditioning (RIC) regimens are increasingly
used for the hematopoietic cell transplantation (HCT) of pediatric and young adult patients with nonma-
lignant diseases. Early experience suggests that these regimens are associated with good survival but a high
incidence of mixed chimerism, which we have previously shown to be inﬂuenced by the alemtuzumab
schedule. We hypothesized that the underlying diagnosis and donor graft source would also affect the
development of mixed chimerism and that the majority of patients would survive RIC HCT without graft loss.
To examine this, we conducted a retrospective study of 206 patients with metabolic diseases, non-Fanconi
anemia marrow failure disorders, and primary immune deﬁciencies who underwent 210 consecutive RIC
HCT procedures at Cincinnati Children’s Hospital. Ninety-seven percent of the patients engrafted. Mixed
donor and recipient chimerism developed in 46% of patients. Patients with marrow failure had a low risk of
mixed chimerism (hazard ratio [HR], .208; 95% conﬁdence interval [CI], .061 to .709; P ¼ .012). The risk of
mixed chimerism was high in patients who received a cord blood graft (HR, 3.122; 95% CI, 1.236 to 7.888; P ¼
.016). As expected, patients who received a proximal or higher dose per kilogram of alemtuzumab schedule
also experienced higher rates of mixed chimerism (all HR > 2, all P < .05). At the time of last follow-up
(median, 654 days; range, 13 to 3337), over 75% of patients had greater than 90% whole blood donor
chimerism. A second transplantation was performed in 5% of patients. Three-year survival without retrans-
plantation was 84% (95% CI, 71% to 98%) for patients who underwent transplantation with an HLA-matched
sibling donor. Survival without retransplantation was negatively affected by lack of a matched related donor,
increasing age, and development of grades III and IV acute graft-versus-host disease. We conclude that
alemtuzumab, ﬂudarabine, and melphalan RIC HCT offers good results for many patients and that the risk of
developing mixed chimerism is inﬂuenced by underlying diagnosis, graft source, and alemtuzumab dosing.
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Reduced-intensity conditioning (RIC) hematopoietic cell
transplantation (HCT) regimens have been introduced over
the last 2 decades to avoid the acute toxicities and compli-
cations of myeloablative regimens. Several RIC regimens are
Table 1
Patient and Transplantation Information
Characteristic Value
No. of patients 206
No. of transplantations 210





HLH, XLP 91 (43%)
CID, CVID 23 (11%)
SCID 24 (11%)
Marrow failure disorder 25 (12%)
Metabolic disorder 22 (10%)
Other 25 (12%)
HLA match
Matched related donor 38 (18%)
Matched unrelated donor 115 (55%)
1 allele mismatch 50 (24%)
2 allele mismatch 7 (3%)
Graft source
Bone marrow 189 (90%)
Cord blood 10 (5%)
Bone marrow þ cord blood 1 (0%)
PBSC 10 (5%)










Distal, 2.5 mg/kg or greater 40 (19%)
Distal, less than 2.5 mg/kg 35 (17%)
Proximal, greater than 1 mg/kg 23 (11%)
Proximal, 1 mg/kg or less 35 (17%)
Other 14 (7%)
GVHD prophylaxis
Methylprednisolone, cyclosporine 147 (70%)
Methylprednisolone with tacrolimus or sirolimus 11 (5%)
Methylprednisolone, cyclosporine, methotrexate 42 (20%)
Other 10 (5%)
XLP indicates X-linked lymphoproliferative disease; CID, combined immune
deﬁciency; CVID, common variable immune deﬁciency; PBSC, peripheral
blood stem cells; TNC, total nucleated cell.
Data presented are n (%) unless otherwise indicated.
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consisting of alemtuzumab, ﬂudarabine, and melphalan are
now commonly employed for pediatric and young adult
patients with primary immune deﬁciencies and metabolic
diseases, and its use is increasing for patients with marrow
failure disorders. In addition to limited acute toxicities, RIC
regimens that contain alemtuzumab are generally associated
with a low incidence of acute graft-versus-host disease
(GVHD). However, RIC regimens are often complicated by the
development of mixed donor and recipient chimerism.
Complete donor chimerism is not necessary to correct most
nonmalignant diseases, but the development of mixed
chimerism is disconcerting, because it can be associated with
eventual graft loss.
To our knowledge, there are no prospective randomized
studies comparing RIC to myeloablative conditioning regi-
mens in pediatric patients with nonmalignant diseases. RIC
HCT outcomes have been reported by several authors but
in mostly small patient series or with heterogeneous
approaches, and there are conﬂicting reports regarding the
clinical signiﬁcance of mixed chimerism [1-9]. Recent series
using RIC regimens have reported high rates of primary or
secondary graft failure, in 16% to 22% of patients, and the loss
of cord blood grafts has been reported to occur in as many as
one third to two thirds of patients [7,10,11]. In contrast, our
group and the Great Ormond Street group have previously
reported low rates of graft failure and retransplantation
despite high rates of mixed chimerism in patients with
hemophagocytic lymphohistiocytosis (HLH) and other pri-
mary immune deﬁciencies [2,9]. We have previously re-
ported that the risk of mixed chimerism is inﬂuenced by the
timing and dose per kilogram body weight of alemtuzumab
in patients with HLH [3]. We hypothesized that the risk of
mixed chimerism after alemtuzumab, ﬂudarabine, and
melphalan RIC HCT in broader patient groups would also be
inﬂuenced by patient diagnosis and by the type of stem cell
graft, and that like patients with HLH, the majority of pa-
tients would survive RIC HCT without graft loss. To examine
this, we conducted a retrospective study of 206 patients with
metabolic diseases, non-Fanconi anemia marrow failure
disorders, and diverse primary immune deﬁciencies who
underwent 210 consecutive RIC HCT procedures at Cincinnati
Children’s Hospital. We observed that alemtuzumab, ﬂu-
darabine, and melphalan RIC HCT offers good results for
many patients and that the risk of developing mixed
chimerism is inﬂuenced by underlying diagnosis, graft
source, and alemtuzumab dosing.METHODS
Patients
Institutional review board permission was granted for this study.
Data were abstracted from the divisional database and we also retro-
spectively reviewed the charts of 206 pediatric and young adult patients
who underwent 210 allogeneic hematopoietic cell transplantations using
alemtuzumab, ﬂudarabine, and melphalan at our center for treatment of
an underlying nonmalignant disorder between August 8, 2004 and May
22, 2013. Patient demographics are summarized in Table 1. Median
patient age at the time of HCT was 4.1 years (range, .24 to 27.2 years).
Patients were classiﬁed into 6 groups based on underlying diagnosis:
HLH and X-linked lymphoproliferative disease (n ¼ 91), combined
immune deﬁciency and common variable immunodeﬁciency (n ¼ 23),
severe combined immune deﬁciency (SCID) (n ¼ 24), non-Fanconi ane-
mia marrow failure disorders (n ¼ 25), metabolic disorders (n ¼ 22),
or other disorders (n ¼ 25). The other disorders category included
immune dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX) syndrome (n ¼ 5), congenital enteropathy (n ¼ 4), autoimmune
lymphoproliferative syndrome (n ¼ 3), chronic granulomatous disease
(n ¼ 2), CD25 deﬁciency (n ¼ 1), DOCK8 deﬁciency (n ¼ 1),hypereosinophilic syndrome (n ¼ 1), interferon gamma receptor 2
deﬁciency (n ¼ 1), Wiskott-Aldrich syndrome (n ¼ 1), X-linked immu-
nodeﬁciency with magnesium defect, Epstein-Barr virus infection, and
neoplasia (n ¼ 1), ill-deﬁned immune deﬁciency (n ¼ 2), sickle cell
disease (n ¼ 1), osteopetrosis (n ¼ 1), and epidermolysis bullosa (n ¼ 1).
Seventy-four of the patients with HLH and X-linked lymphoproliferative
disease have been reported previously [2,3].Transplantation Procedures
Transplantation details are summarized in Table 1. Transplantation
procedures were based on published protocols [3,5,9]. Patients received
ﬂudarabine 150 mg/m2 (5 mg/kg in patients 10 kg or less) divided over
days8 to4 or7 or3 and melphalan 140 mg/m2 (4.7 mg/kg in patients
10 kg or less) on day3 or day2. The dose of ﬂudarabinewas decreased by
20% for 2 patients with renal insufﬁciency. Because of concern for melphalan
toxicity, the dose of melphalan was decreased by 25% to 50% for 2 patients
with renal insufﬁciency, by 50% for 9 patients with a known underlying
diagnosis characterized by DNA repair defects, or by 50% for 1 patient aged 2
months. The schedule of alemtuzumab was modiﬁed over the course of this
report. Patients received alemtuzumab beginning on day 23, 22, or 21
(distal), 14 (intermediate), or 12, 11, 9, or 8 (proximal). Alemtuzu-
mabwas given either as a dose-escalation schedule of 3mg,10mg,15mg, 20
mg (3 mg, 10 mg, 10 mg, 10 mg in patients less than 10 kg) or as a total of 1
mg/kg divided over 5 days, with the ﬁrst dose being no more than 3 mg.
Alemtuzumab was given subcutaneously in 79% of patients, as we began
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venous administration. For the purpose of analyses, patients were classiﬁed
based on receipt of proximal, intermediate, or distal alemtuzumab sched-
ules, with the proximal and distal categories further subdivided by receipt of
above or below the median dose of alemtuzumab per kilogram into the
following categories: proximal greater than 1 mg/kg, proximal 1 mg/kg or
less, intermediate, distal 2.5 mg/kg or greater, and distal less than 2.5 mg/kg.
Fourteen patients were classiﬁed as having received other alemtuzumab
schedules because of acute illness, kidney injury, alemtuzumab reaction,
active HLH, or another issue that prompted adjustment or temporary halt of
alemtuzumab and/or the preparative regimen.
Donor and patient HLA match was determined using clinically
available high-resolution molecular typing for HLA-A, -B, -C, and -DRB1.
For the purpose of analyses, donor and patient HLA match were
categorized as matched related donor (n ¼ 38), matched unrelated
donor (n ¼ 115), donor with 1 allele mismatch (n ¼ 50), and donor with
2 allele mismatch (n ¼ 7). For GVHD analyses, 1 and 2 allele mismatches
were grouped together. Most patients received bone marrow grafts (n ¼
189), whereas a minority received cord blood (n ¼ 10) or peripheral
blood stem cell grafts (n ¼ 10). Peripheral blood stem cell grafts were
selected on the basis of donor preference or inability to give marrow or
large recipient size. One patient received a combined cord blood and
bone marrow graft (from the same sibling donor) but was classiﬁed as
having received bone marrow for all analyses. For patients who received
a subsequent hematopoietic stem cell product “boost,” the product
underwent CD34þ cell selection using the Miltenyi CliniMacs system
(Miltenyi Biotec, Bergisch Gladbach, Germany) in all but 3 cases. T
celledepleted stem cell boosts were given with a maximum T cell dose
limit of 5  104/kg. For patients who received donor lymphocyte in-
fusions (DLI), an infusion was given from product stored from the
original donation or obtained from a subsequent collection from the
original donor, based on the CD3þ cell dose. GVHD prophylaxis con-
sisted of methylprednisolone and cyclosporine (n ¼ 147); methylpred-
nisolone with tacrolimus or sirolimus (n ¼ 11); methylprednisolone,
cyclosporine, and methotrexate (n ¼ 42); or other (n ¼ 10).
All patients received granulocyte colonyestimulating factor, antimi-
crobial prophylaxis, intravenous immunoglobulin replacement, and nutri-
tional and other supportive care per standard clinical practice. Engraftment
studies were performed using XY ﬂuorescence in situ hybridization in the
case of opposite sex donors and short tandem repeat analysis in the case of
same sex donors in the clinical genetics laboratory at Cincinnati Children’s
Hospital. For analysis of lymphocyte subset and myeloid compartment
chimerism, cell types of interest were sorted using the Miltenyi autoMACS
Pro system (Miltenyi Biotec, Bergisch Gladbach, Germany) following a
clinically adapted protocol based on the manufacturer’s instructions in the
Diagnostic Immunology Lab at Cincinnati Children’s Hospital. Acute GVHD
was graded based on consensus criteria [12]. Chronic GVHDwas categorized
as limited or extensive [13].
Deﬁnitions
Neutrophil engraftmentwas deﬁned as the ﬁrst of 3 consecutive days that
the absolute neutrophil count was above 500 cells/mL. Platelet engraftment
was deﬁned as the ﬁrst of 7 consecutive days with a platelet count> 20,000/
mL without platelet transfusion support. Whole blood donor chimerism of
95% or greater was considered to be complete donor chimerism. Mixed
chimerismwas deﬁned as whole blood donor chimerism of less than 95% on
more than 2 consecutive occasions. Secondary graft failure was deﬁned as a
decline of donor chimerism to 0% after achieving neutrophil recovery with
detection of donor chimerism in whole blood samples.
Statistical Analyses
Gray’s method was used to create cumulative incidence curves to
evaluate the impact of several covariates on the development of mixed
chimerism and acute GVHD before 180 or 365 days after HCT using the
cmprsk package in R (version 3.0.1, R Foundation for Statistical Computing,
Vienna, Austria). For the analysis of the cumulative incidence of acute GVHD
in patients with andwithout an initial development of mixed chimerism, we
separately analyzed the time to acute GVHD before or including any inter-
vention for mixed chimerism. Multivariate cause-speciﬁc hazard models
were created using Cox proportional hazards regression using the Survival
package in R to evaluate the impact of covariates on the development of
mixed chimerism and acute GVHD, where death was treated as a censoring
event. Competing risk regression was also performed, where death was
treated as a competing event. Covariates included in the initial models
included age, diagnosis group, HLA match, alemtuzumab category, and graft
source. GVHD prophylaxis and the occurrence of mixed chimerismwere also
included in the GVHD models. For the GVHD analyses, we analyzed the in-
cidences of grades II to IV and III and IV acute GVHD after the initial infusionof the graft alone and also after interventions for mixed chimerism. Final
models were selected using stepwise selection with forward and backward
selection using the stepAIC function of the MASS package in R.
Kaplan-Meier curves were generated to study overall and event-free
survival using XLStat (Addinsoft, Paris, France). Groups were compared us-
ing the log-rank test. An event was deﬁned as death or retransplantation.
Multivariate models were created using Cox proportional hazards regres-
sion using the Survival package in R to evaluate the impact of several
covariates on survival. Covariates included in the initial models included
age, diagnosis category, HLA match and relation, total nucleated cell dose,
alemtuzumab category, occurrence of mixed chimerism, and occurrence of
grades 3 and 4 acute GVHD. The ﬁnal model was selected using stepwise
selection with forward and backward selection. Statistical signiﬁcance was
considered for P < .05.
RESULTS
Initial Engraftment
Two hundred four of the 210 patients (97%) achieved
neutrophil recovery at a median of 11 days after HCT (range,
2 to 48 days). Six patients (3%) died before achieving
neutrophil recovery, at a median of 10 days after HCT (range,
7 to 15 days). Twenty-one patients failed to achieve platelet
engraftment. Five patients did not have decreases in platelet
counts to below 20  103/mL. Of the remaining patients,
platelet recovery was achieved at a median of 20 days after
HCT (range, 6 to 224 days).
Development of Mixed Chimerism
One patient with neutrophil recovery died before an
engraftment study was performed. Of 203 evaluable pa-
tients, initial engraftment studies were performed at a me-
dian of 13 days after HCT (range, 4 to 134 days) and revealed
95% to 100% whole blood donor chimerism in 187 patients
(92%). Over time, a total of 94 of the 203 evaluable patients
(46%) developed whole blood mixed donor and recipient
chimerism, with a median day of onset of 40 days after HCT
(range,10 to 914 days). Ninety-seven percent of patients who
developed mixed chimerism did so before 6 months after
HCT (Figure 1A).
Among patients with mixed chimerism, whole blood
donor chimerism declined to an overall median minimum
of 30% (range, 0 to 93%) at a median time of 149.5 days
after HCT (range, 19 to 1804) (Figure 1B,C). After in-
terventions for mixed chimerism as described below,
mixed chimerism resolved in 39 of the 94 patients (41%)
(Figure 1B,C). At the time of last follow-up (median, 654
days; range, 13 to 3337), over 75% of patients had greater
than 90% whole blood donor chimerism (Figure 1B).
Considering all patients at any time during the ﬁrst 2 years
after HCT, approximately 70% of patients had greater than
95% donor chimerism, 15% had 50% to 95% donor chime-
rism, 5% had 25% to 50%, 5% had 5% to 25%, and 5% had less
than 5% donor chimerism (Figure 1D).
Factors Inﬂuencing the Development of Whole Blood
Mixed Chimerism
As previously reported, the cumulative incidence of
mixed chimerism was highest in patients who received a
proximal schedule of alemtuzumab or distal dosing of 2.5
mg/kg or greater (59% to 70%), versus those who had an
intermediate schedule or distal dosing less than 2.5 mg/kg
schedule (13% to 35%) (P < .001, Figure 2A). There was a
suggestion of increased cumulative incidence of mixed
chimerism in patients who received grafts from mis-
matched donors (P ¼ .139, Figure 2B). Mixed chimerism
was most common in patients who received cord blood
grafts, 78% (P ¼ .001, Figure 2C). Notably, the cumulative
Figure 1. (A) Shows cumulative incidence of mixed chimerism in 203 evaluable patients during the ﬁrst 6 months after HCT. (B) Violin plots showing the distribution
of whole blood donor chimerism in all 203 evaluable patients at initial chimerism testing (median, 13 days; range, 4 to 134 days), time of lowest donor chimerism
(median among patients with mixed chimerism, 149.5 days; range, 19 to 1804 days), and time of last follow-up (median, 654 days; range, 13 to 3337 days). (C) Violin
plots showing the distribution of whole blood donor chimerism just among the 94 patients who developed mixed chimerism at initial chimerism testing (median, 14
days; range, 9 to 35 days), time of lowest donor chimerism (median, 149.5 days; range, 19 to 1804 days), and time of last follow-up (median, 863.5 days; range, 30 to
2968 days). (D) Stacked bar plots of the percentage of patients with >95%, 50% to 94%, 25% to 49%, 5% to 24%, and <5% donor chimerism over time. Of note, patients
who experienced loss of graft (0%) before 3 months after HCT are only included in the 1-, 2-, and 3-month time points.
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patient diagnosis groups except for marrow failure pa-
tients, who experienced a low cumulative incidence of 15%
compared with that of the other diagnosis group rates of
43% to 58% (P ¼ .015, Figure 2D). Multivariate analyses
conﬁrmed the increased risk of developing mixed chime-
rism in patients who receive a proximal alemtuzumab or
distal alemtuzumab 2.5 mg/kg or greater schedule, pa-
tients who receive a cord blood graft, and patients with adiagnosis other than marrow failure (Table 2,
Supplemental Table 1).
Lineage-Speciﬁc Chimerism in Patients with Mixed Whole
Blood Chimerism
Mixed chimerism was evident in the myeloid compart-
ment in all patients for whom myeloid chimerism was
evaluated (n ¼ 25). Mixed chimerismwas evident within the
NK cell and B cell compartments in over 90% of evaluated
Figure 2. Cumulative incidences of mixed chimerism among patients with (A) differing alemtuzumab schedules, (B) HLA match, (C) stem cell source, and (D) un-
derlying diagnosis.
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patients with a diagnosis other than SCID were found to have
mixed chimerism within the T cell compartment (31 of 34),
whereas 6 of 7 evaluated SCID patients maintained greater
than 90% donor-derived T cells.Interventions for Mixed Chimerism and Post-
Intervention Acute GVHD
Interventions for mixed chimerism were directed at the
discretion of the managing physician and are summarized inTable 2
Cause-Speciﬁc Hazard RegressionModel of the Impact of Factors Inﬂuencing
the Development of Mixed Chimerism after HCT (Final Model)
Risk Factor HR (95% CI) P Value
Diagnosis
HLH, XLP 1.0
CID, CVID .783 (.388-1.578) .493
Marrow failure .208 (.061-.709) .012
Metabolic disorder .509 (.198-1.304) .159
SCID .887 (.444-1.771) .733
Other 1.481 (.784-2.779) .226
Stem cell source
Bone marrow 1.0
Cord blood 3.122 (1.236-7.888) .016
PBSC .478 (.115-1.988) .310
Alemtuzumab category
Intermediate 1.0
Distal, 2.5 mg/kg or greater 2.441 (1.174-5.079) .017
Distal, less than 2.5 mg/kg .486 (.181-1.306) .152
Proximal, greater than 1 mg/kg 2.589 (1.349-4.967) .004
Proximal, 1 mg/kg or less 2.322 (1.259-4.281) .007
Other .951 (.319-2.837) .929
Age, diagnosis category, HLA match, graft source, and alemtuzumab cate-
gory were included in the model selection. Death was treated as a censoring
event.Figure 3. Immune suppression was weaned or withdrawn in
most of the 94 cases of mixed chimerism, but 2 patients with
a diagnosis of marrow failure were continued on cyclo-
sporine. Nineteen patients (20%) experienced resolution of
mixed chimerism with reduction or withdrawal of immune
suppression alone. Ten patients developed acute GVHD
grades I to IV after reduction of immune suppression
(without later cell product interventions), and 9 of those 10
experienced resolution of mixed chimerism.
Almost one half of the patients (46 out of 94) with mixed
chimerism were treated with 1 or more cell products as
intervention for mixed chimerism. Mixed chimerism
resolved in 20 of the 46 patients (43%). A hematopoietic stem
cellecontaining product was given to 13 patients at a median
of 132 days after HCT (range, 36 to 815). One or more DLI
were given to 41 patients at a median of 97 days after HCT
(range, 36 to 955). The median T cell dose of the ﬁrst or only
DLI was 1 106 CD3þ/kg (range, .02 to 22.8), and the median
total cumulative Tcell dosewas 11106 CD3þ/kg (range, .1 to
1032). Further details of DLIs are shown in Supplemental
Table 2. Twenty patients developed acute GVHD after DLI
or noneT celledepleted stem cellecontaining product
administration, and ﬁfteen of those patients (75%) experi-
enced resolution of mixed chimerism, versus 24% of patients
who did not develop acute GVHD. We did not observe any
correlation between cumulative DLI dose and the incidence
or grade of GVHD (Supplemental Table 3), with the exception
that no grade II to IV GVHD occurred in patients who
received less than 1  106/kg CD3/kg.Acute GVHD
The development of mixed chimerism was associated
with a lack of development of acute GVHD after the initial
Figure 3. Summary ﬂow chart of interventions for mixed chimerism.
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and III and IV acute GVHD among patients with mixed
chimerism were 1% and 0% before any interventions for
mixed chimerism, respectively, compared with 23% and 18%
among patients who did not develop mixed chimerism (P <
.001 for both comparisons) (Figure 4A,B). However, after
interventions for mixed chimerism as described above, the
cumulative incidences of grades II to IV and III and IV acute
GVHD increased to 25% and 17% in the patients with mixed
chimerism, respectively, essentially equivalent to the rates
observed in the patients who did not develop mixed
chimerism (P¼ .81 and P¼ .74) (Figure 4C,D). The cumulative
incidences of overall acute grades II to IV GVHD and III and IV
GHVD among all patients were 25% (95% conﬁdence interval
[CI], 20% to 32%) and 18% (95 CI%, 14% to 25%), respectively.
Though mixed chimerism protected against the develop-
ment of acute GVHD after the initial graft infusion, the only
covariate that signiﬁcantly inﬂuenced the cumulative inci-
dence of overall acute GVHD grades II to IV and III and IV was
HLA match (Figure 5). This was conﬁrmed by multivariate
analysis (Table 3).
Chronic GVHD
In total, 33 patients (16%) developed chronic GVHD. Ten
patients developed limited chronic GVHD and 23 patients
developed extensive chronic GVHD.
Retransplantation
Three patients experienced secondary graft failure before
30 days after HCT, and 4 patients experienced secondary
graft failure between 37 and 731 days after HCT, all with
autologous recovery. Ten patients (5%) underwent retrans-
plantation at a median of 305 days after the ﬁrsttransplantation (range, 69 to 848 days) due to either graft
failure or low level donor chimerism with reoccurrence of
primary disease symptoms. Six patients underwent
retransplantation using busulfan, cyclophosphamide, and
antithymocyte globulin; 5 are surviving. Alemtuzumab, ﬂu-
darabine, and melphalan RIC HCT was used again for 4 pa-
tients; 1 is surviving.
Overall and Event-Free Survival
Fifty-nine patients died at a median of 181 days after HCT
(range, 7 to 2170 days), with a 1-year probability of overall
survival of 78% (95% CI, 72% to 83%) and a 3-year probability
of overall survival of 69% (95% CI, 62% to 75%).
Because of the 5% incidence of retransplantation, we
focused on analysis of event-free survival (EFS) outcomes,
where an event is deﬁned as death or retransplantation.
Three-year EFS was 84% (95% CI, 71% to 98%) for patients who
underwent transplantation with an HLA-matched related
donor, compared with 64% (95% CI, 55% to 74%), 57% (95% CI,
42% to 71%), and 14% (95% CI, 0 to 40%) for patients who
underwent transplantation with a matched unrelated donor,
1 allele mismatched donor, or 2 allele mismatched donor,
respectively (P < .001) (Figure 6A). Patients who developed
grades III and IV acute GVHD fared worse than patients
without, 40% EFS versus 69% (P ¼ .008) (Figure 6B). Unex-
pectedly, patients who received distal alemtuzumab greater
than 2.5 mg/kg appeared to experience better survival
compared with the other groups (P ¼ .022) (Figure 6C).
Patients with combined immune deﬁciency/common vari-
able immunodeﬁciency and the heterogeneous group of
patients classiﬁed as having other disorders experienced the
lowest survival, whereas patients with metabolic disorders
experienced the highest survival (P ¼ .114) (Figure 6D).
Figure 4. Cumulative incidence of acute GVHD (A) grades II to IV and (B) grades III and IV in patients with and without mixed chimerism, before any interventions for
mixed chimerism. Cumulative incidence of acute GVHD (C) grades II to IV and (D) grades III and IV in patients with and without mixed chimerism including acute
GVHD which occurred after interventions for mixed chimerism (wean or withdrawal of immune suppression, with or without subsequent donor lymphocyte infusion
and/or hematopoietic stem cellecontaining product).
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quartile (older than 8 years) versus the lower 3 quartiles (.2
to 8 years), 53% versus 70% (P ¼ .048) (Figure 6E).
Multivariate analysis conﬁrmed the signiﬁcant impact of
donor-patient HLA match and use of a related or unrelated
donor on EFS (Table 4). Patients who underwent trans-
plantation with a matched unrelated donor (hazard ratio
[HR], 3.04; 95% CI, 1.18 to 7.85; P ¼ .022), 1 allele mismatched
donor (HR, 4.91; 95% CI, 1.78 to 13.55; P ¼ .002), or 2 allele
mismatched donor (HR, 32.19; 95% CI, 8.16 to 127.03; P <
.001) had poorer outcomes compared with patients with
matched sibling donors. Mortality was increased in re-
cipients with grades III and IV acute GVHD (HR, 1.68; 95% CI,
.97 to 2.90; P ¼ .062). The distal alemtuzumab 2.5 mg/kg or
greater group again appeared to have better EFS compared
with the other alemtuzumab groups (HR, .17; 95% CI, .06 to
.53; P ¼ .002). A detrimental effect of older age attransplantation (HR, 1.04; 95% CI, 1.00 to 1.09; P ¼ .037) was
also observed.
Among the patients who died, only 2 deaths were clearly
related to acute toxicity (Table 5). The predominant cause of
death at all time points after HCT was infection (n ¼ 30, 51%
of patients who died). Other causes of death included organ
or multiorgan failure (n ¼ 6), acute GVHD with or without
concurrent infection (n ¼ 4), chronic GVHD with or without
bronchiolitis obliterans and/or pneumonia (n ¼ 6), hemor-
rhage (n ¼ 3), or other causes (n ¼ 8).
DISCUSSION
Our data represent the largest cohort reported to date of
pediatric and young adult patients who consecutively un-
derwent transplantation with alemtuzumab, ﬂudarabine,
and melphalan RIC regimens. For all patients, the cumulative
incidence of mixed chimerism was 46%. However, only 5% of
Figure 5. Cumulative incidence of overall (A) grades II to IV and (B) grades III and IV acute GVHD among patients with differing donor and recipient HLA-match
categories.
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patients possessed greater than 90% whole blood donor
chimerism at the time of last follow-up. Our data support the
continued use of alemtuzumab, ﬂudarabine, and melphalan
RIC HCT for patients with nonmalignant diseases, but there is
a need for frequent analysis of whole blood donor chimerism.
We routinely monitor whole blood chimerism studies
weekly for the ﬁrst several months after HCT. In patients whoTable 3
Multivariate Analysis of Factors Inﬂuencing Development of Overall Grades
II to IV Acute GVHD (Final Model)
Risk Factor HR (95% CI) P Value
HLA match and relation
Matched related donor 1.0
Matched unrelated donor 3.798 (1.318-10.776) .028
1-2 allele mismatched donor 4.539 (1.094-11.198) .016
GVHD prophylaxis, HLA match, graft source, patient age, and alemtuzumab
category were included in the model selection.develop mixed chimerism, interventions including with-
drawal of immune suppression and the use of additional cell
products (most notably DLI) can lead to resolution of mixed
chimerism. Planning for possible DLI should begin at the
time of graft harvest, as lymphocytes can be stored at that
time for later use if the total cell dose allows.
Differences in risk of mixed chimerism were observed in
patients within 2 diagnosis subgroups. Patients withmarrow
failure experienced less whole bloodmixed chimerism, likely
due to poor hematopoietic capability of the patient’s marrow
before HCT. Patients with SCID experienced less mixed
chimerismwithin the Tcell compartment, presumably due to
an intrinsic survival advantage for donor-derived T cells.
Alemtuzumab, ﬂudarabine, and melphalan regimens can,
therefore, be used in these patients with less concern
regarding graft loss or loss of chimerism speciﬁcally in the
cell compartment that was deﬁcient. Differences in risk of
mixed chimerism were also observed with regard to graft
source. Almost all patients who received cord blood grafts
Figure 6. Comparisons of event-free survival of patients based on (A) donor, match and relation, HLA. (B) occurrence of grade III and IV acute GVHD, (C) receipt of
different alemtuzumab schedules, (D) underlying diagnosis, or (E) age group (oldest age quartile versus the lower 3 quartiles).
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ucts are not availablewhen cord blood is used, alemtuzumab,
ﬂudarabine, and melphalan should likely be avoided in pa-
tients for whom a cord blood graft is the best or only option.
As we have noted previously, the highest incidences of
mixed chimerism occurred after proximal schedules and
higher doses of alemtuzumab. The terminal half-life of
alemtuzumab ranges from 6 to 21 days but has signiﬁcant
interpatient variability due to differences in patient quanti-
ties of CD52 antigen [14-17]. Because of the long half-life,alemtuzumab is often still present at the time of graft infu-
sion (and up to 2 months after HCT) and lowers the risk of
GVHD by lymphocyte/T cell depletion of the graft [18-21].
The development of mixed chimerism is likely inﬂuenced by
the extent of T cell depletion of the graft by alemtuzumab,
coupled with the propensity for autologous recovery of pa-
tient bone marrow after the nonablative ﬂudarabine and
melphalan regimen. Alemtuzumab dose de-escalation
studies in adults have resulted in decreased incidences of
mixed chimerism and graft failure, though sometimes with
Table 4
Multivariate Analysis of Event-Free Survival (Final Model)
Risk Factor HR (95% CI) P Value
Age 1.04 (1.00-1.09) .037
TNC dose 1.07 (.98-1.16) .136
Match
Matched related donor 1.00
Matched unrelated donor 3.04 (1.18-7.85) .022
1 allele mismatched donor 4.91 (1.78-13.55) .002
2 allele mismatched donor 32.19 (8.16-127.03) <.001
Alemtuzumab category
Intermediate 1.00
Distal, 2.5 mg/kg or greater .17 (.06-.53) .002
Distal, less than 2.5 mg/kg .99 (.50-1.95) .980
Proximal, greater than 1 mg/kg .43 (.17-1.05) .065
Proximal, 1 mg/kg or less .57 (.27-1.18) .137
Unique .65 (.24-1.70) .376
Occurrence of acute GVHD grades III-IV
No acute GVHD grades III-IV 1.00
Acute GVHD grades III-IV 1.68 (.97-2.90) .062
Age, diagnosis category, HLA match, total nucleated cell dose, alemtuzumab
category, occurrence of mixed chimerism, and occurrence of grades III-IV
acute GVHD were included in the model selection.
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improve immune recovery [17,22-25]. As demonstrated here
and in our previous report [3], an intermediate dosing
regimen of alemtuzumab consisting of 1 mg/kg divided over
days 14 to 10 can be used in pediatric and young adult
patients to decrease the incidence of mixed chimerism. It is
possible that correlation of peritransplantation alemtuzu-
mab levels with pediatric outcomes may lead to optimized
individualized dosing protocols to minimize the incidence of
mixed chimerism. Alternatively, efforts to individualize
melphalan dosing based on patient pharmacokinetics may
help ensure adequate drug exposure and minimize theTable 5
Causes of Death among 59 Patients
Cause n (%)
Infection and complications 30 (51%)
Bacterial
Pseudomonas aeruginosa 7 (12%)
Enterococcus faecium 3 (5%)
Klebsiella pneumonia and Staphylococcus aureus 1 (2%)
Klebsiella pneumonia and Enterococcus faecium 1 (2%)
Acinetobacter baumannii 1 (2%)
Stenotrophomonas maltophilia and Pseudomonas
aeruginosa
1 (2%)
Pneumonia with negative bronchoalveolar lavage 1 (2%)
Fungal
Aspergillus fumigatus 2 (3%)
Scedosporium apiospermum 1 (2%)
Scedosporium proliﬁcans 1 (2%)
Coccidiomycosis 1 (2%)
Pneumocystis jirovecii 1 (2%)
Candida glabrata 1 (2%)
Fungalinfection without identiﬁcation 3 (5%)
Viral
Adenovirus 2 (3%)
Human metapneumovirus and adenovirus 1 (2%)
CMV 2 (3%)
Acute GVHD with or without concurrent infection 4 (7%)









MOF indicates multiorgan failure; VOD, veno-occlusive disease.propensity for recipient marrow recovery. The inclusion of
additional myelosuppressive agents could also be considered
to further prohibit the propensity for recipient marrow re-
covery, and thiotepa and hydroxyurea have already been
added to an alemtuzumab, ﬂudarabine, and lower dose
melphalan (70 mg/m2) regimen in the cord blood setting
with some success [26].
Three-year survival without retransplantation in our
cohort was 84% for patients who underwent transplantation
with a matched related donor graft. Survival was negatively
affected by several factors, including lack of a matched
related donor, development of grades III and IV acute GVHD,
and older age. Unexpectedly, we observed that patients
treated with distal alemtuzumab 2.5 mg/kg or greater
appeared to have better survival. The clinical signiﬁcance of
this observation is uncertain, as despitemultivariate analysis,
this group of patients is intrinsically confounded by young
age (only 1 patient was older than 7 years), and is also
confounded by a preponderance of metabolic disorders. The
high rate of mixed chimerism in this group (59%) argues
against the use of dose escalation schedules of alemtuzumab
in young (small) patients that result in high total doses of
alemtuzumab per kilogram body weight.
Despite the unique complications inherent to alemtuzu-
mab, ﬂudarabine, and melphalan RIC HCT, we conclude that
this approach offers good outcomes for many patients with
nonmalignant diseases, and that the risk of developing
mixed chimerism is inﬂuenced by underlying diagnosis, graft
source, and alemtuzumab dosing. Further advancements will
continue to improve this RIC HCT approach.ACKNOWLEDGMENTS
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